Access

Letters to Nature

Nature 309, 163-165 (10 May 1984) | doi:10.1038/309163a0; Accepted 21 March 1984

Atypical bold italic beta-adrenoceptor on brown adipocytes as target for anti-obesity drugs

J. R. S. Arch, A. T. Ainsworth, M. A. Cawthorne, V. Piercy, M. V. Sennitt, V. E. Thody, C. Wilson & S. Wilson

  1. Beecham Pharmaceuticals, Biosciences Research Centre, Great Burgh, Yew Tree Bottom Road, Epsom, Surrey KT18 5XQ, UK
Top

Recent studies suggest that thermogenesis in brown adipose tissue has an important role in the regulation of energy balance1–7. Thermogenesis is effected by noradrenaline released from sympathetic nerve endings; the noradrenaline stimulates beta;-adrenoceptors, causing lipolysis, and the released fatty acids then promote the uncoupling of oxidative phosphorylation from electron transport8,9. It has been widely accepted10–13 that mammalian beta-adrenoceptors exist as two subtypes, beta1 and beta2 (ref. 14), and rat brown adipocyte beta-adrenoceptors have been classed as beta1 (refs 15–17) or as a mixed beta1/beta2 population18. The beta1 subtype predominates in atria, whereas the beta2 subtype predominates in trachea. However, we have now found a novel group of beta-adrenoceptor agonists that selectively stimulate lipolysis in brown adipocytes. In contrast, isoprenaline, fenoterol and salbutamol are less potent as stimulants of lipolysis than as stimulants of atrial rate or tracheal relaxation. Therefore, beta-adrenoceptors in rat brown adipocytes are of neither the beta1 nor beta2 subtypes. Compounds that selectively stimulate brown adipocyte beta-adrenoceptors should have potential as thermogenic anti-obesity agents and this has been demonstrated with BRL 26830A, BRL 33725A and BRL 35135A.